Your browser doesn't support javascript.
loading
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli, Melinda L; Timms, Kirsten M; Reid, Julia; Hennessy, Bryan; Mills, Gordon B; Jensen, Kristin C; Szallasi, Zoltan; Barry, William T; Winer, Eric P; Tung, Nadine M; Isakoff, Steven J; Ryan, Paula D; Greene-Colozzi, April; Gutin, Alexander; Sangale, Zaina; Iliev, Diana; Neff, Chris; Abkevich, Victor; Jones, Joshua T; Lanchbury, Jerry S; Hartman, Anne-Renee; Garber, Judy E; Ford, James M; Silver, Daniel P; Richardson, Andrea L.
Afiliación
  • Telli ML; Stanford University School of Medicine, Stanford, California.
  • Timms KM; Myriad Genetics Inc., Salt Lake City, Utah.
  • Reid J; Myriad Genetics Inc., Salt Lake City, Utah.
  • Hennessy B; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mills GB; University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jensen KC; Stanford University School of Medicine, Stanford, California.
  • Szallasi Z; Denmark Technical University, Lyngby, Denmark. Children's Hospital Boston, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Barry WT; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Winer EP; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Tung NM; Harvard Medical School, Boston, Massachusetts. Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Isakoff SJ; Harvard Medical School, Boston, Massachusetts. Massachusetts General Hospital, Boston, Massachusetts.
  • Ryan PD; Massachusetts General Hospital, Boston, Massachusetts.
  • Greene-Colozzi A; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Gutin A; Myriad Genetics Inc., Salt Lake City, Utah.
  • Sangale Z; Myriad Genetics Inc., Salt Lake City, Utah.
  • Iliev D; Myriad Genetics Inc., Salt Lake City, Utah.
  • Neff C; Myriad Genetics Inc., Salt Lake City, Utah.
  • Abkevich V; Myriad Genetics Inc., Salt Lake City, Utah.
  • Jones JT; Myriad Genetics Inc., Salt Lake City, Utah.
  • Lanchbury JS; Myriad Genetics Inc., Salt Lake City, Utah.
  • Hartman AR; Myriad Genetics Inc., Salt Lake City, Utah.
  • Garber JE; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ford JM; Stanford University School of Medicine, Stanford, California.
  • Silver DP; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts. Daniel_Silver@DFCI.Harvard.Edu.
  • Richardson AL; Harvard Medical School, Boston, Massachusetts. Dana-Farber Cancer Institute, Boston, Massachusetts. Brigham and Women's Hospital, Boston, Massachusetts.
Clin Cancer Res ; 22(15): 3764-73, 2016 08 01.
Article en En | MEDLINE | ID: mdl-26957554
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Telómero / Pérdida de Heterocigocidad / Desequilibrio Alélico / Recombinación Homóloga / Neoplasias de la Mama Triple Negativas Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Telómero / Pérdida de Heterocigocidad / Desequilibrio Alélico / Recombinación Homóloga / Neoplasias de la Mama Triple Negativas Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article